

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
5 July 2001 (05.07.2001)

PCT

(10) International Publication Number
WO 01/48183 A2

(51) International Patent Classification²: C12N 15/00

(74) Agent: BAYLISS, Geoffrey, Cyril; Boult Wade Tennant,
Verulam Gardens, 70 Gray's Inn Road, London WC1X
8BT (GB).

(21) International Application Number: PCT/EP00/13149

(22) International Filing Date:

22 December 2000 (22.12.2000)

(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ,
DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, L, C, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,
TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(30) Priority Data:

9930691.2 24 December 1999 (24.12.1999) GB

(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (for all designated States except US): DEV-

GEN NV [BE/BE]; Technologiepark 9, B-9052 Zwij-

naarde (BE).

Published:

— Without international search report and to be republished
upon receipt of that report.

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(72) Inventors; and

(75) Inventors/Applicants (for US only): PLAETINCK,
Geert [BE/BE]; Pontstraat 16, B-9820 Merelbeke (BE).
MORTIER, Katherine [BE/BE]; Paddenhoek 20, B-9830
St-Martens-Latem (BE). LISSENS, Ann [BE/BE]; Tiens-
esteenweg 137, B-3010 Kessel-Lo (BE). BOGAERT,
Thierry [BE/BE]; Wolvendreef 26g, B-8500 Kortrijk
(BE).

WO 01/48183 A2

(54) Title: IMPROVEMENTS RELATING TO DOUBLE-STRANDED RNA INHIBITION

(57) Abstract: There are described ways of improving the efficiency of double stranded RNA inhibition as a method of inhibiting gene expression in nematode worms such as *C. elegans*. In particular, the invention relates to the finding that changes in the genetic background of *C. elegans* result in increased sensitivity to double-stranded RNA inhibition.

IMPROVEMENTS RELATING TO DOUBLE-STRANDED RNAINHIBITION

5 The present invention is concerned with ways of improving the efficiency of double stranded RNA inhibition as a method of inhibiting gene expression in nematode worms such as *C. elegans*. In particular, the invention relates to the finding that the 10 susceptibility of nematode worms such as *C. elegans* to double stranded RNA inhibition is affected by changes in the genetic background of the worms.

It has recently been described in *Nature* Vol 391, pp. 806-811, February 98, that introducing double stranded RNA into a cell results in potent and 15 specific interference with expression of endogenous genes in the cell, which interference is substantially more effective than providing either RNA strand individually as proposed in antisense technology. This specific reduction of the activity 20 of the gene was also found to occur in the nematode worm *Caenorhabditis elegans* (*C. elegans*) when the RNA was introduced into the genome or body cavity of the worm.

25 The present inventors have utilized the double stranded RNA inhibition technique and applied it further to devise novel and inventive methods of (i) assigning functions to genes or DNA fragments which have been sequenced in various projects, such as, for example, the human genome project and which have yet 30 to be accorded a particular function, and (ii) identifying DNA responsible for conferring a particular phenotype. Such methods are described in the applicant's co-pending application number WO 00/01846. Processes for introducing RNA into a living 35 cell, either *in vivo* or *ex vivo*, in order to inhibit expression of a target gene in that cell are

CONFIRMATION COPY

NUC 37140

- 2 -

additionally described in WO 99/32619.

Several different experimental approaches can be used to introduce double-stranded RNA into nematode worms in order to achieve RNA interference *in vivo*.

5 One of the most straightforward approaches is simple injection of double-stranded RNA into a body cavity. A more elegant solution is to feed the nematodes on food organisms, generally bacteria, which express a double stranded RNA of the appropriate sequence,

10 corresponding to a region of the target gene.

The present inventors have now determined that the phenomenon of RNA interference in nematodes following ingestion of food organisms capable of expressing double-stranded RNA is dependent both on

15 the nature of the food organism and on the genetic background of the nematodes themselves. These findings may be exploited to provided improved methods of double-stranded RNA inhibition.

Therefore, according to a first aspect of the

20 present invention there is provided a method of inhibiting expression of a target gene in a nematode worm comprising feeding to said nematode worm a food organism which is capable of producing a double-stranded RNA structure having a nucleotide sequence

25 substantially identical to a portion of said target gene following ingestion of the food organism by the nematode, wherein the nematode has a non wild-type genetic background selected to provide increased sensitivity to RNA interference as compared to wild

30 type.

Caenorhabditis elegans is the preferred nematode worm for use in the method of the invention although the method could be carried out with other nematodes and in particular with other microscopic nematodes,

35 preferably microscopic nematodes belonging to the genus *Caenorhabditis*. As used herein the term "microscopic" nematode encompasses nematodes of

approximately the same size as *C. elegans*, being of the order 1mm long in the adult stage. Microscopic nematodes of this approximate size can easily be grown in the wells of a multi-well plate of the type 5 generally used in the art to perform mid- to high-throughput screening.

It is an essential feature of this aspect of the invention that the nematode has a non wild-type 10 genetic background which confers greater sensitivity to RNA interference phenomena (abbreviated herein to RNAi) as compared to the equivalent wild type nematodes. As illustrated in the accompanying 15 examples, introduction of double-stranded RNA (abbreviated herein to dsRNA) into a non wild-type strain according to the invention results in greater inhibition of expression of the target gene. Depending on the nature of the target gene, this greater level of inhibition may be detectable at the phenotypic level as a more pronounced phenotype.

20 The nematode having non wild-type genetic background may, advantageously, be a mutant strain. Mutations which have the effect of increasing 25 susceptibility of the nematode to RNAi may, for example, affect the stability of dsRNA or the kinetics of dsRNA turnover within cells of the worm or the rate of uptake of dsRNA synthesised by a food organism. Suitable mutant strains include mutant strains 30 exhibiting knock-out or loss-of-function mutations in one or more genes encoding proteins involved in RNA synthesis, RNA degradation or the regulation of these processes.

In one preferred embodiment, the nematode is a 35 mutant strain, more preferably a mutant *C. elegans*, which exhibits reduced activity of one or more nucleases compared to wild-type. Suitable strains include mutant strains exhibiting knock-out or loss-of-function mutations in one or more genes encoding

nucleases, such as RNases. A particularly preferred example is the *nuc-1* strain. This mutant *C. elegans* strain is known *per se* in the art.

5 In a second preferred embodiment, the nematode is a mutant strain, more preferably a mutant *C. elegans*, which exhibits increased gut uptake compared to wild-type. Particularly preferred examples of such strains are the so-called *C. elegans* gun mutants described herein. In a still further embodiment, the nematode 10 may be a transgenic worm comprising one or more transgenes which increase gut uptake relative to wild-type.

15 The term "increased gut uptake" as used herein is taken to mean increased uptake of foreign particles from the gut lumen and may encompass both increased gut permeability and increased gut molecular transport compared to wild-type *C. elegans*.

20 *C. elegans* feeds by taking in liquid containing its food (e.g. bacteria). It then spits out the liquid, crushes the food particles and internalises them into the gut lumen. This process is performed by the muscles of the pharynx. The process of taking up liquid and subsequently spitting it out is called 25 pharyngeal pumping. Once the food particles have been internalised via pharyngeal pumping their contents must cross the gut itself in order to reach target sites in the worm. There are multiple factors which effect the uptake of compounds from the gut lumen to the surrounding tissues. These include the action of 30 multi-drug resistance proteins, multi-drug resistance related proteins and the P450 cytochromes as well as other enzymes and mechanisms available for transport of molecules through the gut wall.

35 *C. elegans* mutants which exhibit increased uptake of foreign molecules through the gut may be obtained from the *C. elegans* mutant collection at the C.

elegans Genetic Center, University of Minnesota, St Paul, Minnesota, or may be generated by standard methods. Such methods are described by Anderson in Methods in Cell Biology, Vol 48, "C. elegans: Modern 5 biological analysis of an organism" Pages 31 to 58. Several selection rounds of the PCR technique can be performed to select a mutant worm with a deletion in a desired gene. Alternatively, a population of worms could be subjected to random mutagenesis and worms 10 exhibiting the desired characteristic of increased gut uptake selected using a phenotypic screen, such as the dye uptake method described herein.

As an alternative to mutation, transgenic worms 15 may be generated with the appropriate characteristics. Methods of preparing transgenic worms are well known in the art and are particularly described by Craig Mello and Andrew Fire, Methods in Cell Biology, Vol 48, Ed. H.F. Epstein and D.C. Shakes, Academic Press, pages 452-480.

20 Worms exhibiting the desired characteristics of increased gut uptake can be identified using a test devised by the inventors based on uptake of a marker precursor molecule which is cleaved by the action of enzymes present in the gut lumen to generate a marker 25 molecule which produces a detectable signal, such as fluorescence. A suitable marker precursor molecule is the fluorescent dye precursor BCECF-AM available from Molecular Probes (Europe BV), Netherlands. This dye only becomes fluorescent when cleaved by esterases and 30 maintained at a pH above 6. The pH of the gut lumen is usually 5 or below. Thus, any BCECF-AM taken up through the pharynx into the gut lumen is not 35 fluorescent until cleaved and the cleaved portion has entered the cells surrounding the lumen which are at a higher pH. Thus, this dye is able to quickly identify mutant or otherwise modified worms which have increased gut transport or permeability. There is a

gradual increase in fluorescence in the tissues surrounding the gut while the gut lumen remains dark. The fluorescence can be detected at an excitation wavelength of 485 nm and an emission wavelength of 530 nm.

5 Specific examples of gun mutant strains isolated using this procedure which may be used in the method of the invention are strains bg77, bg84, bg85 and bg86, although it is to be understood that the 10 invention is in no way limited to the use of these specific strains. The *C. elegans* gun mutant strain bg85 was deposited on 23 December 1999 at the BCCM/LMG culture collection, Laboratorium Voor Microbiologie, Universiteit Gent, K. L. Ledeganckstraat 35, B-9000, 15 Gent, Belgium under accession number LMBP 5334CB. The phrase "the bg85 mutation" as used herein refers to the specific mutation(s) present in the bg85 strain which is/are responsible for conferring the gun phenotype.

20 It is also within the scope of the invention to use a non wild-type nematode strain, preferable a *C. elegans* strain, having multiple mutations which affect sensitivity to RNAi. A preferred type of multiple mutant is one having at least one mutation which 25 results in reduced nuclease activity compared to wild type and at least one mutation which results in increased gut uptake compared to wild type. An example of such a mutant is a *C. elegans* strain having the *nuc-1* mutation and at least one further gun 30 mutation. As exemplified herein, double mutants having the *nuc-1* mutation and a gun mutation exhibit enhanced sensitivity to RNAi as compared to either *nuc-1* or gun single mutants.

35 For the avoidance of doubt, where particular characteristics or properties of nematode worms are described herein by relative terms such as "enhanced"

or "increased" or "decreased" this should be taken to mean enhanced, increased or decreased relative to wild-type nematodes. In the case of *C. elegans*, wild-type is defined as the N2 Bristol strain which is well known to workers in the *C. elegans* field and has been extremely well characterised (see Methods in Cell Biology, Volume 48, *Caenorhabditis elegans: Modern biological analysis of an organism*, ed. by Henry F. Epstein and Diane C. Shakes, 1995 Academic Press; The nematode *Caenorhabditis elegans*, ed. by William Wood and the community of *C. elegans* researchers., 1988, Cold Spring Harbor Laboratory Press; *C. elegans II*, ed. by Donald L. Riddle, Thomas Blumenthal, Barbara J. Meyer and James R. Priess, 1997, Cold Spring Harbor Laboratory Press). The N2 strain can be obtained from the *C. elegans* Genetic Center, University of Minnesota, St Paul, Minnesota, USA.

The food organism for use in the above aspect of the invention is preferably a bacterium such as, for example, a strain of *E.coli*. It will, however, be appreciated that any other type of food organism on which nematodes feed and which is capable of producing dsRNA could be used. The food organism may be genetically modified to express a double-stranded RNA of the appropriate sequence, as will be understood with reference to the examples included herein. One convenient way in which this may be achieved in a bacterial food organism is by transforming the bacterium with a vector comprising a promoter or promoters positioned to drive transcription of a DNA sequence to RNA capable of forming a double-stranded structure. Examples of such vectors will be further described below.

The actual step of feeding the food organism to the nematode may be carried out according to procedures known in the art, see WO 00/01846.

Typically the feeding of the food organisms to the nematodes is performed on standard agar plates commonly used for culturing *C. elegans* in the laboratory. However, the step of feeding the food 5 organism to the nematodes may also be carried out in liquid culture, for example in the wells of 96-well microtitre assay plates.

The inventors have further observed that 10 variations in the food organism can result in enhanced *in vivo* RNAi when the food organism is ingested by a nematode worm.

Accordingly, in a further aspect the invention provides a method of inhibiting expression of a target gene in a nematode worm comprising feeding to said 15 nematode worm a food organism capable of producing a double-stranded RNA structure having a nucleotide sequence substantially identical to a portion of said target gene following ingestion of the food organism by the nematode, wherein the food organism carries a 20 modification selected to provide increased expression or persistence of the doubled-stranded RNA compared to a food organism which does not carry the modification.

The modification present in the food organism can 25 be any modification which results in increased expression of the dsRNA or in increased persistence of the dsRNA. Suitable modifications might include mutations within the bacterial chromosome which affect RNA stability and/or degradation or mutations which have a direct effect on the rate of transcription. In 30 a preferred embodiment, the food organism is an RNase III minus *E. coli* strain, or any other RNase negative strain.

According to a still further aspect of the invention there is provided a method of inhibiting 35 expression of a target gene in a nematode worm comprising introduction of a DNA capable of producing a double-stranded RNA structure having a nucleotide

13 sequence substantially identical to a portion of said target gene in said nematode, wherein the nematode is one which exhibits increased gut uptake compared to wild type.

5 In addition to exhibiting increased sensitivity to RNAi following feeding with food organisms capable of expressing a dsRNA, nematodes which exhibit increase gut uptake as described herein also show increased uptake of DNA molecules capable of producing

10 double-stranded RNA structures following ingestion into a nematode.

In a preferred embodiment, the DNA is in the form of a vector comprising a promoter or promoters orientated to relative to a sequence of DNA such that they are capable of driving transcription of the said DNA to make RNA capable of forming a double-stranded structure upon binding of an appropriate RNA polymerase to the promoter or promoters.

20 Several different arrangements of promoters may be used in such a vector. In a first arrangement a DNA fragment corresponding to a region of the target gene is flanked by two opposable polymerase-specific promoters which are preferably identical.

25 Transcription from the opposable promoters produces two complementary RNA strands which can anneal to form an RNA duplex. The plasmid pGN1 described herein is an example of a vector comprising two opposable T7 promoters flanking a multiple cloning site for insertion of a DNA fragment of the appropriate sequence, corresponding to a region of a target gene. pGN8 is an example of a vector derived from pGN1 containing a fragment of the *C. elegans* unc-22 gene. In an alternative arrangement, DNA fragments corresponding to a region of the target gene may be placed both in the sense and the antisense orientation downstream of a single promoter. In this case, the sense/antisense fragments are co-transcribed to

- 10 -

generate a single RNA strand which is self-complementary and can therefore form an RNA duplex.

In both of the above arrangements, the polymerase-specific T3, T7 and SP6 promoters, all of 5 which are well known in the art, are useful for driving transcription of the RNA. Expression from these promoters is dependent on expression of the cognate polymerase. Advantageously, the nematode itself may be adapted to express the appropriate 10 polymerase. Expression of the polymerase may be general and constitutive, but could also be regulated under a tissue-specific promoter, an inducible promoter, a temporally regulated promoter or a promoter having a combination of such characteristics. 15 Transgenic *C. elegans* strains harboring a transgene encoding the desired polymerase under the control of an appropriately-regulated promoter can be constructed according to methods known *per se* in the art and described, for example, by Craig Mello and Andrew Fire 20 in Methods in Cell Biology, Vol 48, Ed. H. F. Epstein and D. C. Shakes, Academic Press, pp 452-480.

The advantage of adapting the nematode to express the required polymerase is that it is possible to control inhibition of expression of the target gene in 25 a tissue-specific and/or temporally specific manner by placing expression of the polymerase under the control of an appropriately regulated promoter.

Introduction of DNA into nematodes in accordance with the method of the invention can be achieved using 30 a variety of techniques, for example by direct injection into a body cavity or by soaking the worms in a solution containing the DNA. If the DNA is in the form of a vector as described herein, e.g. a plasmid harboring a cloned DNA fragment between two flanking 35 T7 promoters, then dsRNA corresponding to this DNA fragment will be formed in the nematode resulting in down regulation of the corresponding gene. The

introduced DNA can form an extrachromosomal array, which array might result in a more catalytic knock-out or reduction of function phenotype. The DNA might also become integrated into the genome of the nematode,
5 resulting in the same catalytic knock out or reduction of function phenotype, but which is stably transmittable.

In each aspect of the invention, the double-stranded RNA structure may be formed by two separate
10 complementary RNA strands or a single self-complementary strand, as described above. Inhibition of target gene expression is sequence-specific in that only nucleotide sequences corresponding to the duplex region of the dsRNA structure are targeted for
15 inhibition.

It is preferred to use dsRNA comprising a nucleotide sequence identical to a portion of the target gene, although RNA sequences with minor variations such as insertions, deletions and single
20 base substitutions may also be used and are effective for inhibition. It will be readily apparent that 100% sequence identity between the dsRNA and a portion of the target gene is not absolutely required for inhibition and the phrase "substantially identical" as
25 used herein is to be interpreted accordingly. Generally sequences which are substantially identical will share at least 90%, preferably at least 95% and more preferably at least 98% nucleic acid sequence identity. Sequence identity may be conveniently
30 calculated based on an optimal alignment, for example using the BLAST program accessible at www.ncbi.nlm.nih.gov.

The invention will be further understood with reference to the following non-limiting Examples,
35 together with the accompanying Figures in which:

Figure 1 is a plasmid map of the vector pGN1

containing opposable T7 promoters flanking a multiple cloning site and an ampicillin resistance marker.

5 Figure 2 is a plasmid map of the vector pGN8 (a genomic fragment of the *C. elegans* unc-22 gene cloned in pGN1).

10 Figure 3 is a plasmid map of the vector pGN29 containing two T7 promoters and two T7 terminators flanking *Bst*XI sites. This vector permits cloning of DNA fragments linked to *Bst*XI adaptors.

15 Figure 4 is a plasmid map of the vector pGN39 containing two T7 promoters and two T7 terminators flanking attR recombination sites (based on the Gateway™ cloning system of Life Technologies, Inc).

20 Figure 5 is a plasmid map of the vector pGX22 (a fragment of the *C. elegans* gene C04H5.6 cloned in pGN29).

25 Figure 6 is a plasmid map of the vector pGX52 (a fragment of the *C. elegans* gene K11D9.2b cloned in pGN29).

Figure 7 is a plasmid map of the vector pGX104 (a fragment of the *C. elegans* gene Y57G11C.15 cloned in pGN29).

30 Figure 8 is a plasmid map of the vector pGZ8 (a fragment of the *C. elegans* gene T25G3.2 cloned in pGN39).

35 Figure 9 shows the results of an RNAi experiment in which wild-type (N2) or *nuc-1* strain *C. elegans* in liquid culture were fed with *E. coli* containing the

plasmid pGX22.

Figure 10 shows the results of an RNAi experiment in which wild-type (N2) or *nuc-1* strain *C. elegans* in 5 liquid culture were fed with *E. coli* containing the plasmid pGX52.

Figure 11 shows the results of an RNAi experiment in which wild-type (N2) or *nuc-1* strain *C. elegans* in 10 liquid culture were fed with *E. coli* containing the plasmid pGXGZ8.

Figure 12 shows the results of an RNAi experiment in which wild-type (N2) or *nuc-1* strain *C. elegans* in 15 liquid culture were fed with *E. coli* containing the plasmid pGX104

Example 1

Influence of genetic background on the efficiency of RNAi in *C. elegans*.

5 **Introduction**

Various different *C. elegans* strains were fed with different bacteria, to test the possibility of RNAi by feeding *C. elegans* with bacteria that produce dsRNA. The possibility of DNA delivery and dsRNA delivery has 10 previously been envisaged by using different bacterial strains. In this experiment the importance of the *C. elegans* strain as receptor of the dsRNA is also shown.

For this experiment the following *E. coli* strains were 15 used:

1. MC1061: F-araD139 Δ (ara-leu)7696 galE15 galK16 Δ (lac)X74 rpsL (Str^r) hsdR2 ($r_b^- m_b^+$) mcrA mcrB1
 - regular host for various plasmids,
 - Wertman et al., (1986) Gene 49:253-262,
 - Raleigh et al., (1989) in Current Protocols in Molecular Biology eds. Ausubel et al, Publishing associates and Wiley Interscience; New York. Unit 1.4.
2. B21(DE3): F- *ompT*(lon) hsdS_B ($r_b^- m_b^-$); an *E. coli* B strain) with DE3, a λ prophage carrying the T7 RNA polymerase gene.
 - regular host for IPTG inducible T7 polymerase expression,
 - Studier et al. (1990) Meth. Enzymol. 185:60-89
3. HT115 (DE3): F- mcrA mcrB IN(rrnD-rrnE) 1 λ -*rnc14::tr10* (DE3 lysogen: lacUV5 promoter-T7polymerase)
 - host for IPTG inducible T7 polymerase

- 15 -

expression,
- RNaseIII-,
- Fire A, Carnegie Institution, Baltimore, MD,
Pers. Comm.

5

For this experiment the following *C. elegans* strains were used:

1. *C. elegans* N2: regular WT laboratory strain
- 10 2. *C. elegans* *nuc-1*(e1393): *C. elegans* strain with a reduced endonuclease activity (>95%); condensed chromatin persists after programmed cell death; ingested (bacterial) DNA in the intestinal lumen is not degraded. Several alleles are described: e1392 (strong allele: has been used for the experiments described below); n887 (resembles e1392) and n334 (weaker allele)
 - Stanfield et al. (1998) East Coast Worm meeting abstract 171,
 - Anonymous, Worm Breeder's Gazette 1(1):17b
 - Hevelone et al. (1988) Biochem. Genet. 26:447-461
 - Ellis et al., Worm breeder's Gazette 7(2):44
 - Babu, Worm Breeder's gazette 1(2):10
- 15 3. Driscoll, (1996) Brain Pathol. 6:411-425
- 20 4. Ellis et al., (1991) Genetics 129:79-94

25

For this experiment the following plasmids were used:

30 pGN1: A vector encoding for ampicillin resistance, harbouring a multiple cloning site between two convergent T7 promoters.

pGN8: pGN1 containing a genomic fragment of *unc-22*.
35 Decreased *unc-22* expression via RNAi results in a "twitching" phenotype in *C. elegans*.

- 16 -

Experimental conditions

12-well micro-titer plates were filled with approximately 2 ml of NGM agar per well (1 litre of NGM agar: 15g Agar, 1g peptone, 3g NaCl, 1ml 5 cholesterol solution (5 mg/ml in EtOH), with sterile addition after autoclaving of 9.5 ml 0.1M CaCl₂, 9.5 ml 0.1 ml MgSO₄, 25 ml 1M KH₂PO₄/K₂HPO₄ buffer pH 6 and 5 ml nystatin solution (dissolved 10 mg/ml in 1:1 EtOH:CH₃COONH₄ 7.5 M).

10 The dried plates were spotted with approximately 50 µl of an overnight culture of bacteria. When IPTG induction was required, 50 µl of a 10 mM stock solution of IPTG was dropped on top of the bacteria lawn, and incubated at 37°C for approximately 4 hours. 15 Individual nematodes at the L4 growth stage were then placed in single wells. In each well 4 nematodes, and the plates were further incubated at 20°C for 6 days to allow offspring to be formed. The F1 offspring of 20 the seeded nematodes were tested for the twitching phenotype.

- 17 -

Results

Table 1: Percentage of the offspring that show the twitching phenotype

	MC1061	N2	<i>nuc-1</i>
5	pGN1	0%	0%
	pGN1 + IPTG	0%	0%
	pGN8	0%	0%
	pGN8 + IPTG	0%	0%
10	BL21 (DE3)		
	pGN1	0%	0%
	pGN1 + IPTG	0%	0%
	pGN8	20% (+)	>90% (++)
	pGN8 + IPTG	20% (+)	>90% (++±)
15	HT115 (DE3)		
	pGN1	0%	0%
	pGN1 + IPTG	0%	0%
	pGN8	50% (+±)	>90% (++)
	pGN8 + IPTG	80% (++)	>90% (+++)
20			

%: percentage twitchers

+: weak twitching

++: twitching

+++: strong twitching

25

Conclusions

The experiment with *E. coli* MC1061 shows that no twitching could be observed in this experiment.

30 Neither the N2 nematodes nor the *nuc-1* nematodes showed any twitchers. This is to be expected as *E. coli* MC1061 does not produce any T7 RNA polymerase, and hence the unc-22 fragment cloned in pGN8 is not

expressed as dsRNA.

5 The experiment with *E. coli* strain BL21(DE3) and
nematode strain N2 shows expected results. BL21(DE3)
harbouring plasmid pGN1 does not result in any
twitching as the pGN1 vector is an empty vector. BL21
(DE3) harbouring PGN8 results in the expression of
unc-22 dsRNA. When this dsRNA is fed to the N2
10 nematode (indirectly by feeding with the bacteria that
produce the dsRNA), this results in a twitching
phenotype, indicating that the dsRNA is able to pass
the gut barrier and is able to perform its interfering
activity.

15 Surprisingly the RNAi effect of the unc-22 dsRNA was
even more pronounced in *C. elegans* strain *nuc-1* than
in the wild type N2 strain. Although one may expect
that the *nuc-1* mutation results in the non-degradation
or at least in a slower degradation of DNA, as the
20 NUC-1 protein is known to be involved in DNase
activity, we clearly observe an enhancement of the
RNAi induced phenotype in *C. elegans* with a *nuc-1*
background. The *nuc-1* mutation has not been cloned
yet, but it has been described that the gene is
25 involved in nuclease activity, and more particularly
DNase activity. If the NUC-1 protein is a nuclease, it
may also have activity on nuclease activity on dsRNA,
which would explain the enhanced RNAi phenotype. The
nuc-1 gene product may be a nuclease, or a regulator
30 of nuclease activity. As the mode of action of RNAi is
still not understood, it is also possible that the
NUC-1 protein is interfering in the mode of action of
RNAi. This would explain why a *nuc-1* mutant is more
sensitive to RNAi.

35

The experiment with the *E. coli* strain HT115 (DE3)

confirms the experiments with the BL21(DE3) strain. The RNA interference observed with the unc-22 dsRNA is even higher. In comparison with strain BL21(DE3) this could be expected, as HT115(DE3) is a RNase III minus 5 strain, and hence is expected to produce larger amounts of dsRNA, resulting in more prominent RNAi. This indicates further that the RNAi observed in this experiment is the result of the dsRNA produced by the bacteria fed to the *C. elegans*. Feeding *C. elegans* 10 *nuc-1* with HT115(DE3) harbouring pGN8 also results in higher RNA interference phenotype than feeding the same bacteria to *C. elegans* wild-type strain N2. Once again this indicates that improved RNAi can be realised using a nuclease negative *C. elegans* and more 15 particularly with a with the *C. elegans nuc-1* (e1392) strain.

Summary

RNA interference can be achieved in *C. elegans* by 20 feeding the worms with bacteria that produce dsRNA. The efficiency of this RNA interference is dependent both on the *E. coli* strain and on the genetic background of the *C. elegans* strain. The higher the level of dsRNA production in the *E. coli*, the more 25 RNAi is observed. This can be realised by using efficient RNA expression systems such as T7 RNA polymerase and RNAase negative strains, such as RNaseIII minus stains. In this example the level of dsRNA production varied: HT115(DE3)>BL21(DE3)>MC1061. 30 RNA interference is high in *C. elegans* strains that are nuclease negative, or that are influenced in their nuclease activity. This can be realised by using a mutant strain such as *C. elegans nuc-1*. 35 In this example the sensitivity to RNAi varied: *C. elegans nuc-1* >> *C. elegans N2*

- 20 -

Example 2

Improved RNAi by feeding dsRNA producing bacteria in selected *C. elegans* strains-Comparison of the *nuc-1* strain with several mutants which show improved gut uptake. (designated herein 'gun' mutants). Strains bg77, bg78, bg83, bg84, bg85, bg86, bg87, bg88 and bg89 are typical gun mutant *C. elegans* strains isolated using selection for increased gut uptake (gun phenotype) with the marker dye BCECF-AM.

10

Experimental conditions:

- 12-well micro-titer plates were filled with approximately 2ml of NGM agar (containing 1ml/l of ampicillin (100 μ g/ml) and 5 ml of 100mM stock 15 IPTG) per well
- the dried plates were spotted with 25 μ l of an overnight culture of bacteria (BL21DE3/HT115DE3) containing the plasmids pGN1 (T7prom-T7prom) or pGN8 (T7prom-unc-22-T7prom)
- individual nematodes at the L4 growth stage were 20 then placed in single wells, one nematode per well
- the plates were incubated at 20°C for 6 days to allow offspring to be formed
- the adult F1 offspring of the seeded nematodes 25 were tested for the twitching phenotype

- 21 -

Results:

Table 2:

	20°C/6d	pGN1 HT115(DE3)	pGN8 BL2DE3	pGN8 HT115(DE3)	
5	N2	0	1	1	
		0	1	1	
		0	1	1	
	bg78	0	1	1-2	
	bg83	0	1	1	
10		0	1	1	
		0	1	1	
		0	1	1	
	bg87	0	1	1	
	bg88	0	1	1	
15	bg89	0	1	1	

figure legend:

- 20 0 = no twitching
- 1 = no to weak phenotype
- 2 = clear phenotype
- 3 = strong phenotype

25 Conclusions

- bacterial strain HT115(DE3) shows a better RNAi sensitivity than bacterial strain BL21(DE3)
- the *nuc-1* *C. elegans* strain is a better strain than the Wild-type N2 strain for RNAi sensitivity
- 30 - various gun mutants (improved gut uptake mutants) and more particularly the gun mutant strains bg77, bg84, bg85, bg86 show improved sensitivity to RNAi compared to Wild-type.

- 22 -

A double mutant *C. elegans* strain (nuc-1/gun) shows even greater sensitivity to RNAi compared to wild-type:

5 Double mutants were constructed to test the prediction that gun/nuc mutants would even show more enhanced RNAi sensitivity. As an example, the crossing strategy with gun strain bg85 is shown, similar crosses can be conducted with other gun strains, such
10 as bg77, bg84 and bg86.

P0 cross: gun(bg85) x WT males

F1 cross: nuc-1 x gun(bg85)/+ males

15 F2 cross: nuc-1 x gun(bg85)/+; nuc-1/0 males (50%)
nuc-1 x +/+; nuc-1/0 males (50%)

20 F3 single: gun(bg85)/+; nuc-1 hermaphrodites (25%)
+ /+; nuc-1 hermaphrodites (75%)

F4 single: gun(bg85); nuc-1 (1/4 of every 4th
plate high staining with BCECF)

25 F5 retest: gun(bg85); nuc-1 (100% progeny of F4
singled high staining with BCECF)

30 To select for the gun phenotype, the fluorescence precursor BCECF-AM is used (obtainable from Molecular probes). The precursor BCECF-AM is cleaved by esterases present in the gut of the worm to generate the dye BCECF which is fluorescent at pH values above 6. This allows selection for worms that have a gun phenotype. BCECF-AM is taken up through the pharynx
35 into the gut lumen and is not fluorescent until it has been cleaved, and the BCECF portion has entered the

cells surrounding the lumen. Wild-type worms will show slower or no increase in BCECF fluorescence.

5 **Example 3**

Improved RNAi feeding in liquid culture using *nuc-1*(e1393) *C. elegans*.

Introduction

10 N2 and *nuc-1* *C.elegans* strains were fed with bacteria producing dsRNAs that give lethal phenotypes via RNAi. For this example RNAi was performed in liquid culture instead of on agar plates. We show here for a number of genes that the RNAi effect is more penetrant using 15 the *nuc-1* strain than the N2 strain, and that RNAi can be performed in liquid.

For this experiment the following *E.coli* strains were used:

20

1. HT115 (DE3): F- *mcrA mcrB* *IN(rrnD-rrnE)* 1 λ -*rnc14::tr10* (DE3 lysogen: lacUV5 promoter -T7 polymerase)
- host for IPTG inducible T7 polymerase expression
- RNaseIII⁻
- Fire A, Carnegie Institution, Baltimore, MD, Pers. Comm.

25 For this experiment, following *C. elegans* strains were used:

1. *C. elegans* N2: regular WT laboratory strain
2. *C. elegans* *nuc-1*(e1393): *C. elegans* strain with a reduced endonuclease activity (>95%); condensed chromatin persists after programmed cell death;

ingested (bacterial) DNA in the intestinal lumen is not degraded. Several alleles are described: el392 (strong allele: has been used for the experiments described below); n887 (resembles el392) and n334 (weaker allele)

5 - Stanfield et al. (1998) East Coast Worm meeting abstract 171

- Anonymous, Worm Breeder's Gazette 1(1):17b

- Hevelone et al. (1988) Biochem. Genet. 26:447-461

10 - Ellis et al., Worm breeder's Gazette 7(2):44

- Babu, Worm Breeder's gazette 1(2):10

- Driscoll, (1996) Brain Pathol. 6:411-425

- Ellis et al., (1991) Genetics 129:79-94

15

For this experiment, the following plasmids that all give lethal phenotypes in *C. elegans* via RNAi were used:

20 pGX22: a vector encoding ampicillin resistance, containing a genomic fragment of cosmid C04H5.6 corresponding to a member of the RNA helicase family.

25 pGX52: a vector encoding ampicillin resistance, containing a genomic fragment of cosmid K11D9.2b corresponding to sarco/endoplasmic Ca^{2+} ATPase also known as SERCA.

30 pGZ18: a vector encoding ampicillin resistance, containing a genomic fragment of cosmid T25G3.2 corresponding to a chitin like synthase gene.

35 pGX104: a vector encoding ampicillin resistance, containing a genomic fragment of cosmid Y57G11C.15 corresponding to sec-61, a transport protein.

Experimental conditions

- 1 ml overnight cultures of HT115 (DE3) bacteria containing the plasmids pGX22, pGX52, pGZ18 or pGX104 respectively were pelleted and resuspended in S-complete medium, containing 1ml/l of ampicillin (100 µg/ml) and 1ml/l of 1000mM IPTG.
- 5
- 10 µl of this bacterial solution was transferred to a 96-well microtiter plate already filled with 100 µl S-complete containing 1ml/l of ampicillin (100 µg/ml) and 1ml/l of 1000mM IPTG.
- 10
- 3 nematodes at the L1 growth stage of N2 and nuc-1 strain were then placed in single wells, 3 L1's per well. Per experimental set up, 16 wells were used (n=16).
- 15
- the plates were incubated at 25°C for 5 days to allow offspring to be formed.
- 20
- the plates were visually checked and the following phenotypes could be scored per individual well:
- 25 **no effect:** L1's developed to adults and gave normal offspring.

 no F1 offspring: L1's developed to adults and gave no offspring.
- 30 **acute lethal:** original L1 did not mature and died.

Results

- 35 The results of this experiment are illustrated graphically in Figures 9 to 12. Data are expressed as

a percentage of the total (n=16) on the y-axis for both N2 and nuc-1 strains.

Conclusions

5 The following genes were tested in this liquid RNAi assay:

- C04H5.6: an RNA helicase. RNAi of this gene interferes with the generation of offspring.
- 10 - SERCA: a sarco/endoplasmic Ca^{2+} ATPase. A strong RNAi phenotype causes an acute lethal phenotype. A less penetrant RNAi effect results in loss of offspring.
- 15 - T25G3.2: a chitin like synthase gene. RNAi of this gene causes dead eggs.
- sec-61: a transport protein. A strong RNAi phenotype causes an acute lethal phenotype. A less penetrant RNAi effect results in loss of offspring.
- 20 - RNAi can be performed under liquid conditions.

As in the previous examples this set of experiments shows that the nuc-1 *C. elegans* strain is more sensitive to RNAi than the wild-type N2 strain. This is most clear for less penetrant phenotypes such as SERCA and chitin synthase. For strong RNAi phenotypes like the helicase and Sec-61 the difference between the N2 wild-type strain and the nuc-1 stain is less pronounced.

30

Example 4

Cloning of pGX22, pGX52, pGZ18 and pGX104 for RNAi

A set of primers for each gene was designed on the basis of sequence data available in the publicly accessible *C. elegans* sequence database (Acedb).

5

The cosmid names relate to:

10 1. C04H5.6=member of RNA helicase
2. K11D9.2b=SERCA
3. Y57G11C.15=transport protein sec-61
4. T25G3.2=chitin synthase like

15 The following primer sequences were designed:

15 1. C04H5.6F 5'-TGCTCAGAGAGTTCTAACGAAACC-3'
C04H5.6R 5'-CAATGTTAGTTGCTAGGACCACCTG-3'

2. K11D9.2bF 5'-CAGCCGATCTCCGTCTTGTG-3'
K11D9.2bR 5'-CCGAGGGCAAGACAACGAAG-3'

3. Y57G11C.15F 5'-ACCGTGGTACTCTTATGGAGCTCG-3'
Y57G11C.15R 5'-TGCAGTGGATTGGGTCTTCG-3'

25 4. T25G3.2F
5'-GGGGACAAGTTGTACAAAAAAGCAGGCTATGCCAAGTACATGTCGATTGCG-3'

T25G3.2R
5'-GGGGACCACTTGTACAAGAAAGCTGGGTTGGAGAACATTCCGAGAGTTG-3'

30

PCR was performed on genomic DNA of N2 strain *C. elegans* to give PCR products of the following sizes:

35 1326bp for C04H5.6
1213bp for K11D9.2b

1024bp for Y57G11C.15

1115bp for T25G3.2

5 The PCR fragments of C04H5.6, K11D9.2b and Y57G11C.15
were linked to *Bst*XI adaptors (Invitrogen) and then
cloned into the pGN29 vector cut with *Bst*XI. pGN29
contains two T7 promoters and two T7 terminators
flanking a cloning site which is adapted for
facilitated cloning of PCR fragments, comprising a
10 stuffer DNA flanked by two *Bst*XI sites (see schematic
Figure 3). The resulting plasmids were designated
pGX22 (C04H5.6), pGX52 (K11D9.2b) and pGX104
(Y57G11C.15).

15 15 The PCR fragment of T25G3.2 was cloned into pGN39 via
recombination sites based on the GATEWAY™ cloning
system (Life Technologies, Inc). pGN39 contains two
T7 promoters and two T7 terminators flanking a cloning
site which facilitates "High Throughput" cloning based
20 on homologous recombination rather than restriction
enzyme digestion and ligation. As shown schematically
in Figure 4, the cloning site comprises attR1 and
attR2 recombination sites from bacteriophage lambda
flanking a gene which is lethal to *E. coli*, in this
25 case the ccdB gene. This cloning site is derived from
the Gateway™ cloning system commercially available
from Life Technologies, Inc. The Gateway™ cloning
system has been extensively described by Hartley et
al. in WO 96/40724 (PCT/US96/10082).

Example 5

Selecting *C. elegans* mutations for increased gut uptake (gun) using marker dye BCECF-AM and *unc-31* as background.

5

The screen was performed in *unc-31*(e928) mutant background, to ensure high amounts of dye in the gut lumen, since *unc-31* mutations show constitutive pharyngeal pumping. The dye (BCECF-AM: 2',7' bis (2-carboxyethyl)-5-(and-6)-carboxyfluorescein, acetoxyethyl ester); obtained from Molecular Probes, is cleaved by intracellular esterases. Fluorescence accumulates in the gut cells upon passage through the apical gut membrane.

15

Mutagenesis

Day 1: *unc-31* L4 staged worms were mutagenised with EMS (final concentration 50 mM) for 4 hours

20

Day 2: P0 was divided over several large agar plates

Day 6: F1's were collected and dropped on large plates. The number of eggs the F1's layed were checked every hour and de F1's were removed when 10-20 eggs per F1 were counted

25

Day 10: F2 adults were collected and screened with BCECF-AM. Mutations with increased staining of the gut cells after 15-30 minutes exposure to the dye were selected and singled on small agar plates.

30

About 50 initial positives gave progeny which was retested with BCECF-AM (2x) and leucine CMB (1x) 9 of the 50 strains were kept (2 strains : 3 times positive, 7 other strains : twice positive)

35

Table 3: Isolation of mutations for increased staining with BCECF-AM

5	Total P0	Total F1	Total F2	screened chromosomes	number of strains isolated
	(counted)	(estimated)	(calculated)	(estimated)	(counted)
	2251	55618	222472	100000	9

Outcrossing, backcrossing and double construction

10 1. backcrossing *unc-31; gun* --> *unc-31; gun*
 - *unc-31; gun* x WT males
 - singled 2x5 WT hermaphrodites F1s (*unc-31/+; gun/+*)
 - singled 50 WT hermaphrodites F2s (1/4 homozygous)
 - select strains segregating 1/4 unc

15 15 - stain unc strains with BCECF-AM
 - from positive strains pick unc homozygous
 - retest 100 % unc strains with BCECF-AM
 - kept 1 strain (backcrossed)

20 20 2. *unc-31* background was crossed out-->+; *gun*
 - *unc-31; gun* x WT males
 - singled 2x5 WT hermaphrodites F1s (*unc-31/+; gun/+*)
 - singled 50 WT hermaphrodites F2s (1/4 homozygous)
 - select strains which did not segregate unc F3s

25 25 anymore
 - stain non unc strains with BCECF-AM
 - 7 positive strains were retested with BCECF-AM and finally 1 was selected and kept (outcrossed)

30 30 3. +; *gun* (1x outcrossed) were 2 times backcrossed-->+; *gun* (3x backcrossed)
 - *gun* x WT males
 - WT hermaphrodites x F1 males (*gun/+*)
 - singled 10 WT hermaphrodites F2s (1/4 heterozygous)

35 35 - singled 50 WT hermaphrodites F3s (1/8 homozygous)

- 31 -

- stain strains with BCECF-AM- retested positives with BCECF-AM and finally 1 was selected and kept

4. *gun* (3x backcrossed) were crossed with *nuc-1*(X)

5 mutant--> *gun*; *nuc-1*

- *gun* x WT males
- *nuc-1* x *gun*/+ males
- *nuc-1* x *gun*/+; *nuc-1*/0 or +/++; *nuc-1*/0 males
- singled 10 WT hermaphrodite progeny (*nuc-1*

10 homozygous, 4 heterozygous *gun*)

- singled 40 WT hermaphrodite progeny (1/8 homozygous *gun*)
- stain strains with BCECF-AM
- retested positives with BCECF-AM and finally 1 was

15 selected and kept

Table 6: Strains derived from *gun* mutations

20	<i>gun</i>	<i>unc-31; gun</i>		<i>unc-31; gun</i>		<i>+/; gun</i>			<i>gun; nuc-1</i>
		original isolate		backcrossed (1x)		outcrossed (1x)		3x b.c.	from 3x b.c.
	allele number	isolation number	strain number	isolation number	strain number	isolation number	strain number	strain number	strain number
25	bg77	31.4	UG 510	31.4.46.1	UG 556	31.4.34	UG 563	UG 674	UG 777
	bg78	37.5	UG 511	37.5.46.4	UG 557	37.5.15	UG 564	UG 675	-
	bg83	10.2	UG 543	10.2.11	UG 600	10.2.21	UG 586	UG 676	-
	bg84	7.2	UG 544	7.2.10	UG 601	7.2.15	UG 589	UG 677	UG 774
	bg85	11.5	UG 545	11.5.29.2	UG 602	2x b.c.	UG 717		UG 775
30	bg86	42.1	UG 546	42.1.4.5	UG 603	42.1.18	UG 587	UG 678	UG 776
	bg87	7.1	UG 547	7.1.8.3	UG 604	7.1.22	UG 585	UG 679	-
	bg88	5.3	UG 548	5.3.9	UG 605	5.3.18	UG 584	UG 680	-
	bg89	23.4	UG 549	23.4.13.5	UG 606	23.4.3	UG 588	UG 671	-

SEQUENCE LISTING:

SEQ ID NO: 1 complete sequence of pGN1

5 SEQ ID NO: 2 complete sequence of pGN8

SEQ ID NO: 3 complete sequence of pGN29

10 SEQ ID NO: 4 complete sequence of pGN39

SEQ ID NO: 5 complete sequence of pGX22

SEQ ID NO: 6 complete sequence of pGX52

15 SEQ ID NO: 7 complete sequence of pGX104

SEQ ID NO: 8 complete sequence of pGZ8

SEQ ID NO: 9 primer C04H5.6F

20 SEQ ID NO: 10 primer C04H5.6R

SEQ ID NO: 11 primer K11D9.2bF

25 SEQ ID NO: 12 primer K11D9.2bR

SEQ ID NO: 13 primer Y57G11C.15F

30 SEQ ID NO: 14 primer Y57G11C.15R

SEQ ID NO: 15 primer T25G3.2F

SEQ ID NO: 16 primer T25G3.2R

Claims:

1. A method of inhibiting expression of a target gene in a nematode worm comprising feeding to said nematode worm a food organism which is capable of producing a double-stranded RNA structure having a nucleotide sequence substantially identical to a portion of said target gene following ingestion of the food organism by the nematode, wherein the nematode 5 has a non wild-type genetic background selected to provide increased sensitivity to RNA interference as compared to wild type.
2. A method as claimed in claim 1 wherein the 10 nematode is a microscopic nematode.
3. A method as claimed in claim 2 wherein the nematode is from the genus *Caenorhabditis*.
- 20 4. A method as claimed in claim 3 wherein the nematode is *C. elegans*.
5. A method as claimed in any one of claims 1 to 4 wherein the nematode has a mutant genetic 25 background.
6. A method as claimed in claim 5 wherein the nematode is a mutant strain which exhibits reduced activity of one or more nucleases compared to wild 30 type.
7. A method as claimed in claim 6 wherein the nematode is *C. elegans* strain nuc-1.
- 35 8. A method as claimed in claim 5 wherein the nematode is a mutant strain which exhibits increased

gut uptake compared to wild type.

9. A method as claimed in claim 8 wherein the nematode is mutant *C. elegans* strain bg85.

5

10. A method as claimed in claim 5 wherein the nematode is a mutant strain having at least one mutation which results in reduced nuclease activity compared to wild type and at least one mutation which 10 results in increased gut uptake compared to wild type.

11. A method as claimed in claim 10 wherein the nematode is a mutant *C. elegans* strain having the *nuc-1* mutation and the bg85 mutation.

15

12. A method as claimed in any one of the preceding claims wherein the food organism has been engineered to express a double-stranded RNA.

20

13. A method as claimed in any one of the preceding claims wherein the food organism is a bacterium.

25

14. A method as claimed in claim 13 wherein the food organism is *E. coli*.

30

15. A method as claimed in any one of the preceding claims wherein the food organism has been genetically modified to express a double-stranded RNA having a nucleotide sequence substantially identical to a portion of said target gene.

35

16. A method as claimed in claim 15 wherein the food organism contains a DNA vector, the vector comprising a promoter or promoters orientated relative to a DNA sequence such that they are capable of

initiating transcription of said DNA sequence to RNA capable of forming a double-stranded structure upon binding of an appropriate RNA polymerase to said promoter or promoters.

5

17. A method as claimed in claim 25 wherein the vector comprises two promoters flanking the DNA sequence.

10

18. A method as claimed in claim 26 wherein the two promoters are identical.

15

19. A method as claimed in claim 25 wherein the vector comprises a single promoter and further comprises said DNA sequence in a sense and an antisense orientation relative to said promoter.

20

20. A method as claimed in any one of claims 16 to 20 wherein the nematode or the food organism is adapted to express an RNA polymerase capable of initiating transcription from said promoter or promoters.

25

21. A method as claimed in any one of claims 16 to 20 wherein the RNA polymerase is T7, T3 or SP6 polymerase.

30

22. A method as claimed in any one of claims 1 to 21 wherein the step of feeding said food organism to said nematode worm is carried out in liquid culture.

35

23. A method of inhibiting expression of a target gene in a nematode worm comprising feeding to said nematode worm a food organism capable of producing a double-stranded RNA structure having a nucleotide sequence substantially identical to a

portion of said target gene following ingestion of the food organism by the nematode, wherein the food organism carries a modification selected to provide increased expression or persistence of the doubled-stranded RNA compared to a food organism which does not carry the modification.

24. A method as claimed in claim 23 wherein the food organism is a bacterium.

10

25. A method as claimed in claim 24 wherein the bacterium is an *E. coli* strain.

15

26. A method as claimed in claim 25 wherein the *E. coli* strain is an RNase III minus strain or any other RNase negative strain.

20

27. A method as claimed in any one of claims 23 to 26 wherein the step of feeding said food organism to said nematode worm is carried out in liquid culture.

25

28. A method of inhibiting expression of a target gene in a nematode worm comprising introduction of a DNA capable of producing a double-stranded RNA structure having a nucleotide sequence substantially identical to a portion of said target gene in said nematode, wherein the nematode is one which exhibits increased gut uptake compared to wild type.

30

29. A method as claimed in claim 28 wherein the nematode is a microscopic nematode.

35

30. A method as claimed in claim 29 wherein the nematode is from the genus *Caenorhabditis*.

31. A method as claimed in claim 30 wherein the

nematode is *C. elegans*.

32. A method as claimed in any one of claims 28 to 31 wherein the nematode has a mutant genetic 5 background.

33. A method as claimed in claim 32 wherein the nematode is mutant *C. elegans* strain bg85.

10 34. A method as claimed in any one of claims 28 to 33 wherein the DNA capable of producing a double-stranded RNA structure is a vector comprising a promoter or promoters orientated relative to a DNA sequence such that they are capable of initiating 15 transcription of said DNA sequence to RNA capable of forming a double-stranded structure upon binding of an appropriate RNA polymerase to said promoter or promoters.

20 35. A method as claimed in claim 34 wherein the vector comprises two promoters flanking the DNA sequence.

25 36. A method as claimed in claim 35 wherein the two promoters are identical.

30 37. A method as claimed in claim 34 wherein the vector comprises a single promoter and further comprises said DNA sequence in a sense and an antisense orientation relative to said promoter.

35 38. A method as claimed in any one of claims 34 to 37 wherein the nematode is adapted to express an RNA polymerase capable of initiating transcription from said promoter or promoters.

39. A method as claimed in any one of claims 34

- 38 -

to 38 wherein the RNA polymerase is T7, T3 or SP6 polymerase.

NUC 37177

FIG. 1.




FIG. 2.




FIG. 3.




FIG. 4.




FIG. 5.




FIG. 6.




FIG. 7.




FIG. 8.




FIG. 9.




FIG. 10.




FIG. 11.





FIG. 12.



1
SEQUENCE LISTING

<110> DEVGEM NV

<120> IMPROVEMENTS RELATING TO DOUBLE-STRANDED RNA INHIBITION

<130> SCB/53711/001

<140>
<141>

<160> 14

<170> PatentIn Ver. 2.0

<210> 1

<211> 3216

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Plasmid pGN1

<400> 1

gagtgcacca tatgcggtgt gaaataccgc acagatgcgt aaggagaaaa taccgcacca 60
 ggcgaaattt taaacgttaa tattttgtta aaattcgcgt taaatatttg ttaaatcagc 120
 tcattttta accaataggc cggaaatcgcc aaaatccctt ataaatcaaa agaatagacc 180
 gagatagggt tgagtgtgt tccagtttgg aacaagagtc cactattaaa gaacgtggac 240
 tccaaacgtca aaggcgaaa aaccgtctat cagggcgtat gcccactacg tgaaccatca 300
 cccaaatcaa gtttttqcg gtcgagggtc cgtaaagctc taaatcgaaa ccctaaagg 360
 agcccccgat tttagacttgc acggggaaag cggcgaacg tggcgagaaa ggaagggaag 420
 aaagcgaaag gacggggcgc tagggcgctg gcaagtgtag cggtcacgct ggcgttaac 480
 acccacacccg cccgccttaa tgcgcggct aaggcgctg ccattcgcca ttcaaggctgc 540
 gcaactgtt ggaagggcga tcgggtcgccc cctcttcgtt attacgccc gtcggcggaaag 600
 ggggatgtgc tgcaaggcga ttaagttggg taacgccagg gtttcccgag tcacgacgtt 660
 gtaaaacgac gcccagtgaa ttgttaatagc actcactata gggcgaattc gagctcggtt 720
 cccggggatc ctctagatgc gaaagcttct cggccctatag ttagtctgtat tacagcttga 780
 gtattctata gtgtcaccta aatagcttgg cgtaatcatg gtcatacgctg ttccctgtgt 840
 gaaattgtt tccgcacca attccacaca acatacgagc cggaagcata aagtgtaaag 900
 cctgggggtgc ctaatgatgc agctaactca cattaattgc gttgcgtca ctggccgctt 960
 tccagtcggg aaacctgtcg tcccgactgc attaataatgat cggccaaacgc ggggggagag 1020
 gcggttgcg tattggcgc tttccgcgtt cctcgctcac tgactcgctg cgctcggtcg 1080
 ttccgctgcg gcgagcggtt tcaatgcact caaaggcggtt aatacggtt tccacaaggat 1140
 caggggatata cgccaggaaag aacatgtga gaaaaggcca gcaaaaggcc aggaaccgta 1200
 aaaaggccgc gttgtggcg ttttcgata ggctccccc cctgacgag catcacaaaa 1260
 atcgacgctc aagttagagg tggcgaaacc cgacagact ataaagatc caggcggttc 1320
 cccctggaaag ctccctcggt cgctctccgtt ttccgacccct gccgcttacc ggataacctgt 1380
 ccgcctttt ccctcggtt agcgtggcgc ttctctatag ctacgctgt aggtatctca 1440
 gttcgggtgtt ggtcggtcg tccaaagctgg gctgtgtgc cgaacccccc gttcagcccg 1500
 acccgctgcgc ctatcccggt aactatcgtc ttgagttccaa cccggtaaga cacgacttat 1560
 cggccactggc agcagccact gtaaacagga ttacgagac gaggtatgtt ggcgtgtca 1620
 cagagttt gaaatgggtt cctaactacg gctacactag aaggacgatg tttggatct 1680
 ggcgtctgtt gaaaggccagg accttcggaa aaagaggttgg tagctctgtt tccggcaaac 1740
 aaaccacccgc tggtagcggt gttttttttt ttgcagaa gcaagatcc cgcagaaaa 1800
 aaggatctca agaagatcct ttgatctttt ctacggggtc tgacgcttag tggaaacggaa 1860
 actcacgtta agggattttt gtcgtatgat tatcaaaaaa gatcttcacc tagatccctt 1920
 taaaattaaaa atgaagttttt aaatcaatct aaagttatata tgagttaaact tgatctgaca 1980

2

gttaccaatg	cttaatcagt	gaggcaccta	tctcagcgat	ctgtctat	ttt	cgttcatcca	2040
tagttgcctg	actccccgtc	gtgttagataa	ctacgatacg	ggagggctta	ccatctggcc	2100	
ccagtgctgc	aatgataccg	cgagacccac	gctcaccggc	tccagattta	tcagcaataa	2160	
accagccacg	cggaggggcc	gagcgcagaa	gtggctctgc	aactttatcc	gcctccatcc	2220	
agtctattaa	ttgttgcggg	gaagctagag	taagttagttc	gccagttaat	agtttgcgca	2280	
acgttgcgttgg	cattgtctaca	ggcatctgtgg	tgtcagcgctc	gtgcgtttgt	atggcttcat	2340	
tcaagtcctgg	ttcccaacgta	tcaaggcgag	ttacatgate	ccccatgttg	tgcaaaaaag	2400	
cggtagtc	cttcggctct	ccgatctgttgc	tcagaagtaa	gttggccgca	gtgttatcac	2460	
tcatgttata	ggcagcaactg	cataattctc	ttactgtcat	gccccatccgt	agatgttctt	2520	
ctgtgactgg	tgagttactca	accaagtcat	tctgagaata	ccgcgcggg	cgaccgagtt	2580	
gctcttgcgc	ggcgtcaata	cgggataata	gtgtatgaca	tagcagaact	ttaaaagtgc	2640	
tcatcatatgg	aaaacgttct	tccggggcgaa	aactctcaag	gatcttaccg	ctgttgagat	2700	
ccagttcgat	gtAACCCACT	cgtgcaccca	actgatctc	agcatctttt	actttcacca	2760	
gcgtttctgg	gtgagcaaaa	acaggaaggc	aaaatgccgc	aaaaaaggga	ataagggcga	2820	
cacggaaatg	ttgaatactc	atactcttcc	tttttcaata	ttattgttgc	atttatcagg	2880	
gttattgtct	catgagcgga	tacatatttt	aatgtat	aaaaaataaa	caaatagggg	2940	
ttccgcgcac	attttcccgaa	aaagtggccac	ctgacgtcta	agaaaaccatt	attatcatga	3000	
cattaaacta	aaaaaatagg	cgtatcacga	ggccctttcg	tctcgcgcgt	ttcggtgat	3060	
acggtaaaa	cctctgacac	atgcagctcc	cgagacgggt	cacagcttgc	ctgtaaaggcg	3120	
atgcggggag	cagacaagcc	cgtcaggggc	cgtcagcggg	tgttggcggg	tgtcggggct	3180	
ggcttaacta	tgcgcacatca	gagcagattt	tactgt			3216	

<210> 2

<211> 4620

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Plasmid pGN8

<400> 2

gatccgaatc	tccatgtctg	ttaacagcct	tgacacgaa	tttatattca	tgcctttag	60
tcaaattcgctc	aacgtggaaag	ttggtatccct	tgctctctcc	gcaagcagtc	catctgccag	120
tggcagcatc	ttgtcttca	atgacatagt	gactgatttc	agtcctccca	tcatcttctg	180
gttcccttcca	tgcaagatca	catccatccct	tgacaattat	agtgacatcg	agaggtccac	240
gtgggcttga	tggatgatca	agaacagtaa	ccttcatttc	ageagtgtca	gttccattt	300
cgttctctgc	cttgcgtatca	tagttccctg	tatccgaacg	caaagcttc	ttcacatgga	360
atttagcttc	gccgtctca	ttgttcaact	tcatacatc	atcagattcg	actgggttc	420
cttcgaagat	ccaagtaatt	gttggagtt	gttcaccact	gactggaaatg	ttcaatgaga	480
agtcttgc	agccttgacc	ttgatttctt	gaatcgagtt	acgatcgatg	actggtgaa	540
ctataattta	attcaatgat	tattagtaat	tgatttagac	tcttaccatt	tctagcctt	600
gcaacagctg	atgctgaatc	agatggatct	cccaatctg	ccttggttctt	ggcacggatt	660
ctgaattctgt	actttgatcc	ttccttgaga	tttccaaacag	tagcatcgat	ttgtccagct	720
ggaacatgag	caacgtcatt	ccagaatggc	gagaactcgt	ccttcatttc	aacaacgtat	780
tcctcgattt	gagcaccacc	gtcgtttgc	ggtggttcc	attcaaggtc	aacatgatcc	840
ttatcccaat	cagtaatttc	aggagcattt	gtctttctg	gcttgtcaaa	tggatctt	900
gcaagtgtgg	ttccgaaggt	ctccaatgga	tcggactctc	cttcagcatt	gacggcagcg	960
acacggaaact	gaaaatcaaa	atgtttagg	caattgagtt	caagattaaa	aaattctcac	1020
tttatattca	tgccaggaa	taagaccgtc	aacaacagct	gtagtcttat	ctccagcgac	1080
ctttgcagct	ggaacccatc	ttccacttgc	agtatcgatc	tttcgatca	catagtttc	1140
aattggaaa	cctccatcat	catactgggt	acgccaattc	aaagtgcacat	gatcaccatg	1200
aaacatcgaa	acatataatg	gaccatttg	aaaggtggc	ttgtctgaaa	atttaaaat	1260
taaccaaattt	aattgaagaa	aactaatgtc	caccaataac	attgtatc	acagttgtt	1320
catcttctcc	atttgcattt	acagctttga	tagtggaaatg	tccactgtct	ccacgttca	1380
tttgcitca	aaccagctt	gattggatt	ctgggttatac	aagcttctcg	ccctatagtg	1440
agtcgttata	cagcttgagt	attctatagt	gtcacctaaa	tagcttggcg	taatcatgg	1500
catagcttt	tcctgtgtga	aattgttattc	cgctcacaat	tccacacaaac	atacgagccg	1560
gaagcataaaa	gtgtaaaagcc	ttgggtgcct	aatgagttag	cttaactcaca	ttaattgcgt	1620

3

<210> 3
<211> 4756

<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Plasmid pGX22

catcattgga aaacgttctt cggggcgaaa actctcaagg atcttaccgc tttttagatc 3420
 cagttcgatg taacccactc gtgcacccaa ctgatcttca gcatcttta ctttaccag 3480
 cgtttctggg ttagcaaaaa caggaaggca aaatgccca aaaaaggaa taagggcgc 3540
 acggaaatgt tgaatactca tactcttct ttttcaatat tattgaagca tttatcagg 3600
 ttattgtctc atgagcggat acatattga atgtatgg aaaaataaac aaatagggt 3660
 tccgcgcaca tttcccgaa aagtgcacc tgacgtctaa gaaaccatta ttatcatgac 3720
 attaacctat aaaaataggc gtatcacgag gcccttcgt ctcgcgcgt tcgggtatga 3780
 cggtaaaaac ctctgacaca tgcagctcc ggagacggc acagcttgc ttaagccga 3840
 tgcggggagc agacaagcc gtcagggcgc gtcagcgggt gttggcgggt gtcgggctg 3900
 gcttaactat gcgcatcg agcagattt actgagatg caccatatgc ggtgtgaaat 3960
 accgcacaga tgcgtaaagg aaaaataccg catcaggcg aattgtaaac ttatattt 4020
 tttttttttt cgcgttaaat atttgttta tcagtcatt tttttaacca tagggcggaa 4080
 tcggcaaat cccttataaa tcaaaaagaat agacccgat aagggttgat gttgtccag 4140
 tttggaccaa ggtccacta ttaaagaac tggactccaa cgtcaaaagg cgaaaaaccg 4200
 tctatcaggg cgatggccca ctacgtaaac catcacccaa atcaagttt ttgcggcga 4260
 ggtgcgttaa agtcttaat cggaaaccctt aaggagcccc cggattttaga gcttgacggg 4320
 gaaagccggc gaacgtggcg agaaaggaaag ggaagaaagc gaaaggagcg ggcgctagg 4380
 cgctggcaag ttagcggcgt acgctgcgcg taaccaccac acccgccgcg cttaatgcgc 4440
 cgctacaggc cgctccatt cgccatttcg gctgcgcac ttttgggaaag ggcgatcggt 4500
 gcccggctct tcgttattac gccagcttgc gaaagggggaa tttgtctgc ggcgatattaa 4560
 ttgggttaaoc ccagggtttt cccagtcacg acgtgttaaa acgacggccca gtgaatttga 4620
 atacgactca ctataggcg aattcaaaaa accctcaag accccgtttag aggccccaag 4680
 gggttatgtc agtgaatttgc cggggatccct ctagagatcc ctcgaccccg 4740
 agatccattt tgctgg 4756

<210> 4
 <211> 4643

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Plasmid pGX52

<400> 4

gagtgcacca tatgcgggtgt gaaataccgc acagatgcgt aaggagaaaa taccgcattca 60
 ggcgaattt gaaacgttaa tattttgttta aatttcgcgt taaatattt ttaatcagc 120
 tcattttta accaataggc cggaaatccgc aaaaatccctt ataaatcaaa agaatacgacc 180
 gagatagggt ttagtgggtgt tccagtttgg aacaagatc cactattaaa gaacgtggac 240
 tccaacgtca aaggcgaaa aaccgtctat cagggcgatg gcccactacg tgaaccatca 300
 cccaaatcaa gtttttgcg gtcgagggtgc cgtaaagctc taaatcgaa ccctaaagg 360
 agcccccgtt ttagagcttgc acggggaaag cggcgaacg tggcgagaaa ggaaggaaag 420
 aaagcgaaag gaggccgcg tagggcgtg gcaagtgttag cggtcacgcg ggcgttaacc 480
 accacaccccg cccgcgttaa tgcgcgcgt cagggcggtt ccattcgcctt ttcaggctgc 540
 gcaactgttgc ggaaggcgaa tccgtgcggg cctcttcgtt attacgcacg ctggcgaaag 600
 ggggatgtgc tcaaggcgaa ttaagtggg ttaacgcagg gttttcccaacg tcacgacgtt 660
 gtaaaaacgc ggcgtgaa ttgtatatacg actactata gggcaattt aaaaaaccccc 720
 tcaagaccccg tttagaggcc ccaagggtt atgctgtga attctgcagg gtacccgggg 780
 atcctctaga gatccctcgat cctcgatgtc cattgtgtgc gcaagccgatc tccgttctgt 840
 gaagatctac tccaccacca tccgtatcgat tcgtccatc ctcaccggag aatctgtgtc 900
 ttttatcaag cacaccgact ctgtgcaga tccacgcgtt gttaccagg acaagaagaa 960
 ttgtctgttc tcgggaacca atgtcgatc tggaaaggct cgtggatcg tcttcggaaac 1020
 cggattgacc actgaaatcg gaaagatccg taccggaaatg gtcgagaccc agaatgagaa 1080
 gacaccactt caacagaatg tggacgatc cggagacca ctttccaagg ttatctctgt 1140
 tatttgcgtt gctgtttggg ctatcaacat tggacatttc aacgatccag ctcacgggtgg 1200
 atcatgggtt aaggagacca tctactactt caaaatcgcc gttgtcttgc cctgcgtgc 1260
 tattccagaa ggacttccag ctgtcatcac cacgtgcctt gcccctcgaa ctcgcctat 1320
 ggccaagaag aacgctattt gaaatccct tccatccgtc gaaacttgc gatgcacatc 1380
 ttttatctgc tctgacaaga ctggactctt caccaccaac cagatgtctg ttttcaaaatg 1440

gttcatcgct ggacaagctt ctggagacaa catcaacttc accgagttcg ccatctccgg 1500
 atccacctac gagccagtc gaaaggtttc caccaatgga cgtaaaatca acccagctgc 1560
 tggagaattc gaatcactca ccgagttgc catgatctgc gctatgtca atgattcata 1620
 tggattac aatgagacca agaagatcta cgagaaaagtc ggagaagcca ctgaaaactgc 1680
 tcttatcggtt cttgtgaga agatgaatgt tttcggaaacc tcgaaaagccg gactttcacc 1740
 aaaggagctc ggaggagttt gcaaccgtgt catccaacaa aatggaaga aggagttcac 1800
 actcgagttc tcccggtatc gtaaatccat gtccgcctac tgcttcccaag cttccggagg 1860
 atctggagcc aagatgttc tgaagggagc cccagaagga gttctcgaa gatgcaccca 1920
 cgtcagagtt aacggacaaa agtttccact cacctctgcc atgactcaga agattgtta 1980
 ccaatgcgtg caatacgaa caatggatct cgagggatct ccggaaagaga tacccttcgt tgccttgc 2040
 tactagcata accccttggg gcctctaaac ggttcttgag 2100
 gggtttttgc agtttctcgcc tccatataatc tgcgtattac agtttgcgttgc 2160
 tcaatggatctt agtttgcgtt gctcataatc agtttgcgttgc 2220
 gtcacaatt ccacacaaca atgagtggac taactcacat aatgcgttgc 2280
 cctgtcgatc cagctgcatt tggcgctct tccgttccct 2340
 agcggatca gtcactcaa agggccatc aatggccagg aaccgttaaaa aggccgcgtt 2400
 gctggcgttt ttcgtatggc tcaatggatctt aatgcgttgc 2460
 tcagagggtgg cgaacccccga cggactata aagataccag gctgttccct 2520
 cctgtcgatc tccgttgc 2580
 agcggatca gtcactcaa aaggccatc aacggatcc acagaatcag gggataacgc 2640
 agggccatc aatggccagg aaccgttaaaa aggccgcgtt 2700
 tccggccccc tgcgtatggc caggactata aagataccag gctgttccct 2760
 cgttgcgttgc 2820
 ctcatagtc acgttgcgttgc 2880
 atccgttaac ttcgttgc 2940
 agtcaatggc aacggatca gtcactcaa aatggccagg aaccgttaaaa aggccgcgtt 3000
 gtcgtatggc gtcgtatggc gtcgtatggc 3060
 acactagaag gacagtattt gtcgtatggc 3120
 gagttggtag ctctgtatcc gcaacacaaa ccaccgcgtt 3180
 gcaaggcgtc gattacgcgc agaaaaaaaag gatctcaaga 3240
 cggggctgtc cgtctactgtt aacggatcc cactggcagc 3300
 caaaaaggat cttcacccat atccttttaa attaaaaatg 3360
 gtatataatc gtaaacttgg tctgacatcc accaatgttt 3420
 cagcgtatcc tctatccatc tcatccatc ttgcctgact 3480
 cgatacgggaa gggcttacca tctggccccc gtcgtcaat 3540
 caccggctcc agattatca gcaataaaacc agccagccgg 3600
 gtccgtcaac tttatccgc tccatccatc ctattaaattt 3660
 gtagttcgatcc agttaatagt ttgcgtcaac ttgttggcat 3720
 cacgctcgatcc gtttggatg gtcgtatccatc gtcgtatggc 3780
 catgatcccc catgttgc aaaaaaggcg 3840
 gaagtaatggc gtcgtatggc ttatcactca ttgttgc 3900
 ctgtcatgcc atccgtatcc tgcgtatggc tgactgtgt 3960
 gagaataccg cgccggcgatcc cggagttgc 4020
 tatgacatag cagaacttta aatgtgtca tcattggaaa 4080
 ttcgtatggc ttcgtatggc ttgttgc 4140
 gatcttgcgtc atcttttactt ttcaccagcg ttctgggtg 4200
 atccgtatcc aatggatcc aatggatcc gtcgtatggc 4260
 ttcaatattt ttgttgc ttcgtatggc ttgttgc 4320
 gtatggatcc aatggatcc aatggatcc gtcgtatggc 4380
 acgttcaatggc aatggatcc aatggatcc gtcgtatggc 4440
 ctttcgtatcc gtcgtatggc ttgttgc 4500
 agacggatcc agtgcgtatcc ttcgtatggc ttgttgc 4560
 cagcgggtgt ttcgtatggc cggggctggc ttcgtatggc 4620
 ggcgtatccatc cagattgtac tga 4643

<210> 5
 <211> 4454
 <212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Plasmid pGX104

<400> 5

gagtgcacca tatgcggtgt gaaataccgc acagatgcgt aaggagaaaa taccgcata 60
 ggcggaaattt gaaacgttaa tattttgtt aatttcgcgt taaatattt ttaaatcagc 120
 tcattttta accaataggc cggaaatccgc aaaatccctt ataaatcaaa agaatagacc 180
 gagatagggt tgagtgtgt tccagttgg aacaagagtc cactattaa gaacgtggac 240
 tccaaacgtca aaggcgaaa aaccgtctat cagggcgatg gcccactacg tgaaccatca 300
 cccaaatcaa gtttttgcg gtcgagggtc cgtaaagctc taaatcgaa ccctaaaggg 360
 agcccccgat ttagagctt acggggaaag cccggcaacg tggcgagaaa ggaagggaaag 420
 aaagcgaaag gaggggcgc accacacccg cccgcgtttaa gcaactgttg ggaaggcgaa 480
 ggggatgtgc tgcaaggcgaa tttagaggcc tcaagatggg taacgcagg gttttcccg tcacgcacgtt 540
 gtaaaacgcac ggcgcgtttaa ttgtataatcg actactata gggcgaattt aaaaaacccc 600
 tcaagacccg ttagaggcc atcctctaga gatccctcgat gctcggaaatc tcacttctgg 660
 gatcatcgaa gtcggagaca taaggcggaaa agtgtgtgtt tcacatctt aattttgaa ccaagggggtt 720
 tcacatctgtt tggacaagctt attcgtactgaa ttctctatcg cattgtctg gaccgtggta 780
 ctcccgatcactt cttttccctt ctcggatcactt ctccaaagg gatatggctt cggatccgaa 840
 tcatttccatcgaa caacatctgtt ttcacatctt aatttttgcgtt ttcacatctt 900
 acaccggacg tggaaaccggat cccgctccgaa caagggtccgt tcatgttgcgtt ttcacatctt 960
 tgatgaactt gatggctactt tcatttccatcgaa caacatctgtt ttcacatctt 1020
 gtgtcgaccc tccaaatcaag gaaaccattt gatatggctt cttttccatcgaa 1080
 agctcttca cacccttcaac attcgttgcgtt ttcacatctt 1140
 acgttatctc tcagggtttgtt ttcacatctt 1200
 aggtcaagt tggccgagaa ttctctatcgaa caacatctgtt ttcacatctt 1260
 tttttccatcgaa gatatggctt cttttccatcgaa 1320
 gtttccatcgaa caacatctgtt ttcacatctt 1380
 ttctctatcgaa caacatctgtt ttcacatctt 1440
 tcatttccatcgaa caacatctgtt ttcacatctt 1500
 attccaatca tcacatctt 1560
 tgcatctcgat ttcacatctt 1620
 attttttgcgtt ttcacatctt 1680
 aagttccgtt ttcacatctt 1740
 ttcacatctt 1800
 tcacatctt 1860
 tcacatctt 1920
 aaccccttgcgtt ttcacatctt 1980
 agtcttgcgtt ttcacatctt 2040
 catagcttgcgtt ttcacatctt 2100
 gaagcataaa gtttccatcgaa 2160
 ttcacatctt 2220
 tcacatctt 2280
 ttcccttccatcgaa 2340
 agtcttgcgtt ttcacatctt 2400
 tacgttgcgtt ttcacatctt 2460
 aaaaggccatcgaa 2520
 ttccatcgaa 2580
 gtttccatcgaa 2640
 cttttccatcgaa 2700
 aaccccttgcgtt ttcacatctt 2760
 ctatcgatcactt 2820
 taacaggatt agcagagcgaa 2880
 taactacggc tacactagaa 2940
 cttcgaaaa agagttggta 3000
 ttttttgcgtt ttcacatctt 3060
 gatcttgcgtt ttcacatctt 3120

catgagatta	tcaaaaagga	tcttcaccta	gatccttta	aattaaaaat	gaagttttaa	3180
atcaatctaa	agtatatatg	agtaaacttg	gtctgacagt	taccaatgt	taatcagtga	3240
ggcacctatc	tcagcgatct	gtctatttcg	ttcatccata	gttgcctgac	tccccgtcgt	3300
gtagataact	acgatacggg	agggcttacc	atctggccc	agtgtcgaa	tgataccgcg	3360
agacccacgc	tcacccggctc	cagatttatac	agcaataaaac	cagccagccg	gaagggccga	3420
gcbcagaatg	ggtcctgcaa	ctttatccgc	ctccatccag	tctattaatt	gttgcggga	3480
agctagagta	agttagtgcg	cagttaataag	tttgcgcac	gttggttggca	ttgctacagg	3540
catcggtgt	tcacgctcg	cgttggat	ggcttcattc	agtcgggtt	cccaacgcac	3600
aaggcgagt	acatgatccc	ccatgttgc	caaaaaacgc	gttagtcct	tcggctcc	3660
gatcggtgtc	agaagtaagt	ttggcccgat	gttatactc	atgtttatgg	cagcaactgca	3720
taattcttt	actgtcatgc	catccgtaa	atgctttct	gtgactgggt	agtactcaac	3780
caagtcatc	tgagaatacc	gcccggcg	accgagg	tcttgcggg	cgtcaataacg	3840
ggataatagt	gtatgacata	gcagaactt	aaaagtgtc	atcatggaa	aacgttcttc	3900
ggggcgaaaa	ctctcaagga	tcttaccgc	gttgagatcc	agttcgatgt	aacccactcg	3960
tgcacccaaac	tgatcttcag	catctttac	tttccaccage	gttctgggt	gagcaaaaac	4020
aggaaggccaa	aatggcccaa	aaaagggaat	aaggcgaca	cgaaaatgtt	gaatactcat	4080
actcttcctt	tttcaatatt	attgaagcat	ttatcagggt	tattgtctca	tgagcggata	4140
catatggaa	tgtatggaa	aaaataaaca	aatagggggt	ccgcgcacat	ttcccccggaaa	4200
agtgcacact	gacgtctaa	aaaccattat	tatcatgaca	ttaacctata	aaaataggcg	4260
tatccacgg	cccttcgtc	tcgcgcgtt	cggtgatgc	gttggaaaacc	tctgacacat	4320
gcagctcccg	gagacggta	cagttgtct	gtaagcggat	gccccggagca	gacaaggcccg	4380
tcagggcgcg	tcagcgggt	ttggcggtt	tcggggctgg	cttaactatg	cgccatcaga	4440
gcagattgt	ctgaa					4454

<210> 6
<211> 4701
<212> DNA
<213> Arti

<220>
<223> Description of Artificial Sequence: Plasmid pgZ18

```

<400> 6
acccagctt cttgtacaaa gtggtgatct ttccagcaca atggatctcg agggatcttc 60
catacctacc agttctgcgc ctgcaggatcg cggccgcgac tctctagacg cgtaaagctta 120
ctagcataac cccttggggc ctctaaacgg gtcttgaggg gttttttag gttctcgccc 180
tatagtgagt cgtattacag cttgaggtatt ctatagtgtc acctaaatag cttggcgtaa 240
tcatggtcat agctgtttcc tgggtgaaat tggtatccgc tcacaattcc acacaacata 300
cgagccggaa gcataaaatg taaaggcttg ggtgcctaat gaggtagcta actcacat 360
attcgcttgc gtcactgccc cgctttccag tcgggaaacc tggctgtccca gctgcattaa 420
tgaatcgccgg aacgcgggg gagaggccgtt ttgcgtattt ggcgtcttc cgcttctcg 480
ctcaactgact cgctgcgtc ggtcggtcg ctgcggcgag cggatcagc tcaactcaaag 540
gccccgtaatc ggttatccac agaatacggg gataacgcag gaaagaacat gtgagcaaaa 600
ggccagcaaa aggccaggaa cctgtaaaaag gccgcgttgc tggcggtttt cgataggctc 660
cgccccctcg acgagcatca caaaaatcgca cgctcaagtc agaggtggcg aaaccgcaca 720
ggactataaa gataccaggc gtttccccct ggaagctccc tcgtgcgtc tcctgttccg 780
accctggccgc ttaccggata cctgtccgccc ttctccctt cgggaagcgt ggcgttttct 840
catagctcac gctgttagta tctcgttgc gtgttagtgc ttgcctccaa gctgggctgt 900
gtgcacgaaac ccccccgttca gcccgcaccgc tgccgccttat ccggtaaacta tgcgttcttgag 960
tccaaccccg taagacacgaa cttatcgcca ctggcagcag ccactggtaa caggattaa 1020
agagcgaggt atgttaggcgg tgctcatacgag ttcttggtaa ggtggcctaa ctacggctac 1080
actagaagga cagtattttg tatctcgctc ctgcgtaaagc caggatccctt cggaaaaaaga 1140
gttggtagt cttgtatccgg caaacaaaacc accgcgttgc gccgtgggtt ttttgggttc 1200
aagcagcaga ttacggcag aaaaaaaggaa tctcaagaag atcccttgc tttttctacg 1260
gggtctgacg ctcagtgaa cggaaaactca cgttaaggga ttttgggtcat gagattatca 1320
aaaaggatct tcacccatagat ctttttaat taaaaatgaa gttttaaattc aatctaaatg 1380
atatatgagt aaacttggtc tgacagttac caatgtctaa tcagtgaggc acctatctca 1440
gcgtatctgtc tatttcgttc atccatagtt gcctgactcc ccgtcggtta gataactacg 1500

```

atacggggagg	gcttaccatc	tggcccccagt	gctgcaatga	taccgcgaga	ccacacgctca	1560
ccggctccag	atttatcagc	aataaaccag	ccagccggaa	ggggcggagcg	cagaagtgg	1620
cctgcaacct	tatccgcctc	catccagtct	attaatgtt	gccccggaa	tagagtaag	1680
agttcgccag	ttaatagttt	gcgcaacgtt	gttggcattt	ctacaggcat	cgtgggtgtca	1740
cgctcgctgt	ttggtatggc	ttcattcagc	tccggttccc	aacatcaag	gcgagttaca	1800
tgatccccca	tggtgtgcaa	aaaagcggtt	agctccctcg	gtctccgtat	cggtgtca	1860
agtaagtgg	ccgcgtgtt	atcaactcatg	gttatggcag	cactgcataa	ttctcttaact	1920
gtcatgcac	cctgtaaatgt	cttttctgtt	actgggtagt	actcaacca	gtcattctga	1980
gaataccgg	cccgccgacc	gagttgtct	tgcccgctgt	caatacggga	taatagtgt	2040
tgacatagca	gaactttaaa	agtgtctatc	atggaaac	gttctccggg	gcgaaaactc	2100
tcaaggatct	taccgctgtt	gagatccagt	tcgatgtaa	ccactctgtc	acccaactga	2160
tcttcagcat	cttttacttt	caccagcggt	tctgggtgag	caaaaacagg	aaggcaaaa	2220
gcccggaaaa	agggaataag	ggcgacacgg	aaatgtgaa	tactcataact	cttcctttt	2280
caatattatt	gaagcattta	tcagggttat	tgtctcatga	gcggatatacat	atttgaatgt	2340
attnagaaaa	ataaacaat	aggggttccg	cgcacatttc	ccggaaaagt	gccacctgac	2400
gtctaagaaa	ccattattat	catgacattt	acctataaaa	ataggcgtat	cacgaggccc	2460
tttcgtctcg	cgcggttccg	tgatgacggt	gaaaacctct	gacacatgca	gtccccggag	2520
acggtcacag	cttgcgttca	agcggatgccc	gggagcacag	aaggccgtca	gggcgcgtca	2580
gccccgttgc	gggggtgtcg	gggctgtcc	aactatgcgg	catcagagca	gattgtactg	2640
agatgtcacc	atatgcgtt	tgaataatccg	cacatgtcg	taaggagaaa	ataccgcata	2700
aggcgaaatt	gtaaacgtt	atattttgtt	aaaatgcgt	ttaaattttt	gtttaatctag	2760
ctcattttt	aaccaatagg	ccgaaatcg	caaaaatccct	tataaattcaa	aagaatagac	2820
cgagataggg	tttagtgtt	ttccagttt	gaacaagagt	ccactattaa	agaacgtgga	2880
ctccaacgtc	aaagggcgaa	aaaccgtcta	tcagggcgat	ggcccactac	gtgaaccatc	2940
acccaaatca	agtttttgc	gttcgagggt	cgtaaagct	ctaaatcgga	accctaaagg	3000
gagcccccg	tttagagctt	gacggggaaa	gcccggaaac	gtggcgagaa	aggaagggaa	3060
gaaagcgaaa	ggagccggcg	ctagggcgct	ggcaagtgt	gcgtcagcgc	tgccgttaac	3120
caccacaccc	ggccgcgtta	atgcgcgcgt	acagggcg	tccattcgcc	attcaggctg	3180
cgcaactgtt	gggaaggcg	atcggtgcgg	gcctcttcgc	tattacgcca	gttggcgaaa	3240
gggggatgt	ctgcaaggcg	atagaatgtt	gttaaccccg	ggtttttccca	gtcacaacgt	3300
tgtaaaacga	ccggcgtgt	attgtataatc	gactcaat	aggcgaatt	caaaaaaccc	3360
ctcaagaccc	gttagaggc	ccaaaggggt	tatgtctat	aattctgcag	gttaccccg	3420
gatcctctag	agatccctcg	acctcgagat	ccattgtgt	ggaaagcctt	tgccaggctg	3480
gcaagccacg	tttgggtgt	gggaccatcc	tccaaaatca	acaagttgt	acaaaaaaagc	3540
aggctatgc	aagtacatgt	cgattgcgt	cgcgttgc	atgttgcgt	tgttagtgc	3600
taccagcgt	caaattgtt	tcgagagtgc	gtttttacat	tatcccttca	tcctgattac	3660
gacaatttc	agctgttctc	gtccttacat	ctctcttcat	tgtcacaatg	gtcggaaatc	3720
tcttccttgc	tgcattgtt	catccaaaag	aattcagaa	tattatccat	gtgtcgat	3780
tcttcctct	gattccatct	acatatgtgt	tccttcattt	atattcgctc	atcaatctca	3840
acgttatac	gtggggact	cgtgaagct	tcgctaaggc	aacgggacaa	aagacgaaaa	3900
aagcgctat	ggaacaattt	atagacagag	tgattgtat	tgtaaaaaaag	ggattcatgt	3960
taatcagg	tcgggagaag	aaggaacatg	aagagagacg	agaaaaatg	aaaaagaaaa	4020
tgcagagaat	ggagctagcc	ttgagaagta	ttgaggttat	ctttaacttt	aaatgttga	4080
aattaataat	ttatatttgc	agtgggtccg	acgtgaagaa	aattctcgat	gcaacagagg	4140
agaaggagaa	acgtgaagaa	gaaactcaaa	ctgcagattt	tccgattgaa	gagaacgtag	4200
agaagactca	aaaagagatt	cagaaggca	accgttatgt	gtggatgaca	agtcatagct	4260
tgaaagtgg	tgaacgagga	aaactgtaaaa	gtgcggaaaa	ggttttctgg	aacgagctca	4320
tcaatgcata	tctgaaaccg	atcaagacga	cgccagctga	aatgaaagcc	gtccggaaag	4380
gattggctt	tctacgaaat	cagattgttt	tcactattct	tctctgtt	tctcttcttg	4440
ctcttgcatt	cttttgatt	cagaacacca	aaaatgtgt	cacgtcaag	ttctcgccaa	4500
tcaatgcata	atattacattt	tatgtgtcaat	tcaaaaaatt	tgtttttttt	ttcttagaaaa	4560
cttccgtatgg	acgaaaatgt	atagatgac	tggacaatac	gagaaacccg	atgaaccatt	4620
aaaaatagat	ccacttggaa	tgggattgt	tgttttccctt	cttaatttac	tttttgttca	4680
aactctcgaa	atgtttctcc	a				4701

<210> 7
<211> 25
<212> DNA

10

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:
Oligonucleotide primer C04H5.6F

<400> 7

tgctcagaga gtttctcaac gaacc

25

<210> 8

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Oligonucleotide
primer C04H5.6R

<400> 8

caatgttagt tgcttaggacc acctg

25

<210> 9

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Oligonucleotide
primer K11D9.2bF

<400> 9

cagccgatct ccgtcttgtg

20

<210> 10

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Oligonucleotide
primer K11D9.2bR

<400> 10

ccgagggcaa gacaacgaag

20

<210> 11

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Oligonucleotide
primer Y57G11C.15F

<400> 11

accgtggtagt tcttatggag ctcg

24

<210> 12

11

<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:Oligonucleotide
primer Y57G11C.15R

<400> 12
tgcagtggat tgggtcttcg

20

<210> 13
<211> 52
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:Oligonucleotide
primer T25G3.2F

<400> 13
ggggacaagt ttgtacaaaa aagcaggctt tgccaaatgtcgattt cg

52

<210> 14
<211> 52
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:Oligonucleotide
primer T25G3.2R

<400> 14
ggggaccact ttgtacaaga aagctgggtt ggagaagcat tccgagatgt tg

52